10-Q 1 d10q.htm FORM 10-Q Form 10-Q
Table of Contents

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 

 

FORM 10-Q

 

 

 

x Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

For the quarterly period ended January 31, 2008

OR

 

¨ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

For the transition period from                      to                     

Commission file number 0-5286

 

 

KEWAUNEE SCIENTIFIC CORPORATION

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   38-0715562

(State or other jurisdiction of

incorporation or organization)

 

(I.R.S. Employer

Identification No.)

2700 West Front Street

Statesville, North Carolina

  28677
(Address of principal executive offices)   (Zip Code)

(704) 873-7202

(Registrant’s telephone number, including area code)

 

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes    x    No    ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer    ¨    Accelerated filer     ¨    Non-accelerated filer    ¨    Smaller reporting company    x

(Do not check if a

smaller reporting company)

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).    Yes    ¨    No    x

As of March 3, 2008, the Registrant had outstanding 2,552,420 shares of Common Stock.

 

 


Table of Contents

KEWAUNEE SCIENTIFIC CORPORATION

INDEX TO FORM 10-Q

FOR THE QUARTERLY PERIOD ENDED JANUARY 31, 2008

 

           

Page Number

PART I.      FINANCIAL INFORMATION   
Item 1.      Financial Statements   

Consolidated Statements of Operations - Three and nine months ended January 31, 2008 and 2007

   3

Consolidated Balance Sheets January 31, 2008 and April 30, 2007

   4

Consolidated Statements of Cash Flows - Nine months ended January 31, 2008 and 2007

   5

Notes to Consolidated Financial Statements

   6
Item 2.      Management’s Discussion and Analysis of Financial Condition and Results of Operations    9
     Review by Independent Registered Public Accounting Firm    13
     Report of Independent Registered Public Accounting Firm    14
Item 3.      Quantitative and Qualitative Disclosures About Market Risk    15
Item 4.      Controls and Procedures    15
PART II.      OTHER INFORMATION   
Item 6.      Exhibits    16
SIGNATURE    17

 

2


Table of Contents

Part 1. Financial Information

Item 1. Financial Statements

Kewaunee Scientific Corporation

Consolidated Statements of Operations

(Unaudited)

(in thousands, except per share data)

 

     Three months ended
January 31
    Nine months ended
January 31
 
     2008     2007     2008     2007  

Net sales

   $ 21,883     $ 18,041     $ 67,394     $ 58,720  

Costs of products sold

     17,064       14,417       52,759       47,888  
                                

Gross profit

     4,819       3,624       14,635       10,832  

Operating expenses

     3,293       2,829       9,811       8,365  
                                

Operating earnings

     1,526       795       4,824       2,467  

Other income (expense)

     (6 )     (11 )     (2 )     33  

Interest expense

     (86 )     (142 )     (302 )     (524 )
                                

Earnings before income taxes

     1,434       642       4,520       1,976  

Income tax expense

     421       207       1,391       613  
                                

Earnings before minority interests

     1,013       435       3,129       1,363  

Minority interests

     211       114       441       340  
                                

Net earnings

   $ 802     $ 321     $ 2,688     $ 1,023  
                                

Net earnings per share

        

Basic

   $ 0.32     $ 0.13     $ 1.07     $ 0.41  

Diluted

   $ 0.31     $ 0.13     $ 1.05     $ 0.41  

Weighted average number of common shares outstanding (in thousands)

        

Basic

     2,543       2,492       2,523       2,492  

Diluted

     2,576       2,493       2,551       2,493  

See accompanying notes to consolidated financial statements.

 

3


Table of Contents

Kewaunee Scientific Corporation

Consolidated Balance Sheets

(in thousands)

 

     January 31,
2008
    April 30,
2007
 
     (Unaudited)        

Assets

    

Current assets:

    

Cash and cash equivalents

   $ 2,427     $ 2,231  

Restricted cash

     455       372  

Receivables, less allowance

     19,791       19,061  

Inventories

     6,130       5,869  

Deferred income taxes

     298       297  

Prepaid expenses and other current assets

     924       684  
                

Total current assets

     30,025       28,514  

Property, plant and equipment, at cost

     38,364       37,096  

Accumulated depreciation

     (26,796 )     (25,841 )
                

Net property, plant and equipment

     11,568       11,255  

Prepaid pension cost

     2,256       1,911  

Deferred income taxes

     134       129  

Other

     3,575       3,431  
                

Total other assets

     5,965       5,471  

Total Assets

   $ 47,558     $ 45,240  
                

Liabilities and Stockholders’ Equity

    

Current liabilities:

    

Short-term borrowings

   $ 3,673     $ 3,489  

Current obligations under capital leases

     351       360  

Accounts payable

     7,669       8,437  

Employee compensation and amounts withheld

     1,500       1,416  

Deferred revenue

     710       1,672  

Other accrued expenses

     1,451       809  
                

Total current liabilities

     15,354       16,183  

Obligations under capital leases

     219       476  

Accrued employee benefit plan costs

     3,445       3,351  

Minority interests in subsidiaries

     1,685       1,182  
                

Total Liabilities

     20,703       21,192  

Stockholders’ equity:

    

Common stock

     6,550       6,550  

Additional paid-in-capital

     360       155  

Retained earnings

     22,105       19,947  

Accumulated other comprehensive loss

     (1,732 )     (1,833 )

Common stock in treasury, at cost

     (428 )     (771 )
                

Total stockholders’ equity

     26,855       24,048  
                

Total Liabilities and Stockholders’ Equity

   $ 47,558     $ 45,240  
                

See accompanying notes to consolidated financial statements.

 

4


Table of Contents

Kewaunee Scientific Corporation

Consolidated Statements of Cash Flows

(Unaudited)

(in thousands)

 

     Nine months ended
January 31
 
     2008     2007  

Cash flows from operating activities:

    

Net earnings

   $ 2,688     $ 1,023  

Adjustments to reconcile net earnings to net cash used in operating activities:

    

Depreciation

     1,429       1,428  

Provision for bad debts

     184       112  

Deferred income tax expense

     (5 )     —    

Decrease (increase) in receivables

     (914 )     4,613  

Increase in inventories

     (261 )     (137 )

Increase in prepaid pension cost

     (345 )     (286 )

Decrease in accounts payable and other current liabilities

     (42 )     (2,412 )

Increase (decrease) in deferred revenue

     (962 )     152  

Other, net

     313       388  
                

Net cash provided by operating activities

     2,085       4,881  

Cash flows from investing activities:

    

Capital expenditures

     (1,742 )     (1,415 )

Increase in restricted cash

     (83 )     (14 )
                

Net cash used in investing activities

     (1,825 )     (1,429 )

Cash flows from financing activities:

    

(Decrease) increase in short-term borrowings

     184       (2,169 )

Payments on capital leases

     (266 )     (222 )

Dividends paid

     (530 )     (524 )

Proceeds from exercise of stock options (including tax benefit)

     548       —    
                

Net cash used in financing activities

     (64 )     (2,915 )
                

Increase in cash and cash equivalents

     196       537  

Cash and cash equivalents, beginning of period

     2,231       929  
                

Cash and cash equivalents, end of period

   $ 2,427     $ 1,466  
                

See accompanying notes to consolidated financial statements.

 

5


Table of Contents

Kewaunee Scientific Corporation

Notes to Consolidated Financial Statements

(unaudited)

A. Financial Information

The unaudited interim consolidated financial statements of Kewaunee Scientific Corporation (the “Company” or “Kewaunee”) have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (the “Commission”). Accordingly, certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted, although the Company believes that the disclosures are adequate to make the information presented not misleading.

These interim consolidated financial statements should be read in conjunction with the financial statements and notes included in the Company's 2007 Annual Report to Stockholders. The results of operations for the interim periods are not necessarily indicative of the results of operations to be expected for the full year.

The preparation of the consolidated financial statements requires management to make certain estimates and assumptions that affect reported amounts and disclosures. Actual results could differ from those estimates.

B. Inventories

Inventories consisted of the following (in thousands):

 

     January 31, 2008    April 30, 2007

Finished products

   $ 1,087    $ 1,243

Work in process

     1,400      1,257

Raw materials

     3,644      3,369
             
   $ 6,130    $ 5,869
             

For interim reporting, LIFO inventories are computed based on year-to-date quantities and interim changes in price levels. Changes in quantities and price levels are reflected in the interim consolidated financial statements in the period in which they occur.

 

6


Table of Contents

C. Comprehensive Income

A reconciliation of net earnings and total comprehensive income for the three and nine months ended January 31, 2008 and 2007 is as follows (in thousands):

 

     Three months ended
January 31, 2008
    Three months ended
January 31, 2007

Net earnings

   $ 802     $ 321

Change in cumulative foreign currency translation adjustments

     (69 )     20
              

Total comprehensive income

   $ (733 )   $ 341
     Nine months ended
January 31, 2008
    Nine months ended
January 31, 2007

Net earnings

   $ 2,688     $ 1,023

Change in cumulative foreign currency translation adjustments

     (101 )     35
              

Total comprehensive income

   $ 2,587     $ 1,058

Assets and liabilities for the Company’s foreign subsidiaries are translated at exchange rates prevailing on the balance sheet date. Revenues and expenses are translated at weighted average exchange rates prevailing during the period and any resulting translation adjustments are reported separately in shareholders’ equity.

D. Segment Information

The following table provides financial information by business segments for the three and nine months ended January 31, 2008 and 2007 (in thousands):

 

     Domestic
Operations
   International
Operations
   Corporate     Total

Three months ended January 31, 2008

          

Revenues from external customers

   $ 17,659    $ 4,224    $ —       $ 21,883

Intersegment revenues

     303      66      (369 )     —  

Operating earnings (loss) before income taxes

     1,565      601      (732 )     1,434

Nine months ended January 31, 2008

          

Revenues from external customers

     55,753      11,641      —         67,394

Intersegment revenues

     1,566      376      (1,942 )     —  

Operating earnings (loss) before income taxes

     5,506      1,234      (2,220 )     4,520

 

7


Table of Contents
     Domestic
Operations
   International
Operations
   Corporate     Total

Three months ended January 31, 2007

          

Revenues from external customers

   $ 14,714    $ 3,327    $ —       $ 18,041

Intersegment revenues

     971      594      (1,565 )     —  

Operating earnings (loss) before income taxes

     749      440      (547 )     642

Nine months ended January 31, 2007

          

Revenues from external customers

     48,424      10,296      —         58,720

Intersegment revenues

     2,834      1,051      (3,885 )     —  

Operating earnings (loss) before income taxes

     2,573      1,193      (1,790 )     1,976

E. Defined Pension Plans

The Company has non-contributory defined benefit pension plans covering substantially all salaried and hourly employees. Effective April 30, 2005, no further benefits will be earned under the plans and no additional participants will be added to the plans. At April 30, 2007, the plans’ assets at fair value exceeded benefit obligations by $1.9 million. No contributions were paid to the plans during the nine months ended January 31, 2008, and the Company does not expect any contributions to be paid to the plans during the remainder of the current year.

Pension expense (income) consisted of the following (in thousands):

 

     Three months ended
January 31, 2008
    Three months ended
January 31, 2007
 

Service Cost

   $ -0-     $ -0-  

Interest Cost

     215       210  

Expected return on plan assets

     (365 )     (346 )

Amortization of prior service costs

     -0-       -0-  

Recognition of net loss

     35       41  
                

Net periodic pension cost (income)

   $ (115 )   $ (95 )
     Nine months ended
January 31, 2008
    Nine months ended
January 31, 2007
 

Service Cost

   $ -0-     $ -0-  

Interest Cost

     645       631  

Expected return on plan assets

     (1,095 )     (1,039 )

Amortization of prior service costs

     -0-       -0-  

Recognition of net loss

     105       122  
                

Net periodic pension cost (income)

   $ (345 )   $ (286 )

 

8


Table of Contents

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

The Company’s 2007 Annual Report to Stockholders contains management's discussion and analysis of financial condition and results of operations at and for the year ended April 30, 2007. The following discussion and analysis describes material changes in the Company’s financial condition since April 30, 2007. The analysis of results of operations compares the three and nine months ended January 31, 2008 with the comparable periods of the prior fiscal year.

Results of Operations

Sales for the three months ended January 31, 2008 were $21,883,000, an increase of 21.3% from sales of $18,041,000 in the same period last year. Sales from domestic operations increased 20.0% from the same period last year to $17.7 million. Sales from international operations increased 26.9% from the same period last year to $4.2 million.

Sales for the nine months ended January 31, 2008 were $67,394,000, an increase of 14.8% from sales of $58,720,000 in the same period last year. Sales from domestic operations increased 15.1% from the same period last year to $55.8 million. Sales from international operations increased 13.1% from the same period last year to $11.6 million. The total order backlog was $58.8 million at January 31, 2008. This compares to $54.9 million at October 31, 2007 and $48.6 million at January 31, 2007.

The gross profit margin for the three months ended January 31, 2008 was 22.0% of sales, as compared to 20.1% of sales in the comparable quarter of the prior year. The gross profit margin for the nine months ended January 31, 2008 was 21.7%, as compared to 18.4% in the comparable period of the prior year. The gross profit margin improvements in the current year periods resulted primarily from increased manufacturing efficiencies, savings from alternate sources for raw materials and components, and other cost improvement activities.

Operating expenses for the three months ended January 31, 2008 were $3.3 million, or 15.0% of sales, as compared to $2.8 million, or 15.7% of sales, in the comparable period of the prior year. Operating expenses for the nine months ended January 31, 2008 were $9.8 million, or 14.6% of sales, as compared to $8.4 million, or 14.2% of sales, in the comparable period of the prior year. The absolute dollar increase in operating expenses for the three and

 

9


Table of Contents

nine months ended January 31, 2008, and the increase in operating expenses as a percent of sales for the nine months ended January 31, 2008, resulted primarily from increased costs associated with incentive plans, sales and marketing expenses, and Sarbanes-Oxley and other consulting expenses.

Operating earnings of $1,526,000 and $4,824,000 were recorded for the three and nine months ended January 31, 2008, respectively, compared to $795,000 and $2,467,000 recorded for the comparable periods of the prior year.

Interest expense was $86,000 and $302,000 for the three and nine months ended January 31, 2008, respectively, compared to $142,000 and $524,000 for the same periods of the prior year. The decrease in interest expense for the current year periods resulted primarily from lower borrowing levels.

Other income/expense was expense of $6,000 and $2,000 in the three and nine months ended January 31, 2008, respectively, compared to expense of $11,000 in the three months ended January 31, 2007 and income of $33,000 in the nine months ended January 31,2007.

Income tax expenses of $421,000 and $1,391,000 were recorded for the three and nine months ended January 31, 2008, respectively, as compared to income tax expense of $207,000 and $613,000 recorded for the comparable periods of the prior year. The effective tax rate was 29.4% and 30.8% for the three and nine months ended January 31, 2008, respectively, and was 32.2% and 31.0% for the three and nine months ended January 31, 2007, respectively. The effective tax rates for each of these periods differs from the statutory rate due to varying income tax rates associated with the earnings of foreign subsidiaries, and to a lesser extent, the impact of earned state and federal income tax credits.

Minority interest related to the Company’s two foreign subsidiaries that are not 100% owned by the Company reduced net earnings by $211,000 and $441,000 for the three and nine months ended January 31, 2008, respectively, as compared to minority interest expense of $114,000 and $340,000 during the comparable periods of the prior year. The increases in minority interest for the current year periods resulted from increased earnings of the related subsidiaries.

Net earnings of $802,000, or $0.31 per diluted share, and $2,688,000, or $1.05 per diluted share, were recorded for the three and nine months ended January 31, 2008, respectively. This compares to net earnings of $321,000, or $0.13 per diluted share, and $1,023,000, or $0.41 per diluted share, for the three and nine month periods of the prior year.

 

10


Table of Contents

Liquidity and Capital Resources

Historically, the Company’s principal sources of liquidity have been funds generated from operations, supplemented as needed by short-term borrowings under the Company’s revolving credit facility. Additionally, certain machinery and equipment are financed by non-cancelable operating leases or capital leases. The Company believes that these sources will be sufficient to support ongoing business requirements, including capital expenditures through the current fiscal year.

The Company had working capital of $14.7 million at January 31, 2008, compared to $12.3 million at April 30, 2007. The ratio of current assets to current liabilities was 2.0-to-1 at January 31, 2008, as compared to 1.8-to-1 at April 30, 2007. At January 31, 2008, advances of $3,673,000 were outstanding under the bank credit facility, as compared to $3,489,000 at April 30, 2007.

The Company’s operations provided cash of $2,085,000 during the nine months ended January 31, 2008. Cash was provided primarily from earnings, which was partially offset by a decrease in deferred revenue and an increase in receivables. The Company’s operations provided cash of $4,881,000 during the nine months ended January 31, 2007. During this period, cash was provided primarily from earnings and a decrease in accounts receivable, which were partially offset by a decrease in accounts payable and other current liabilities.

During the nine months ended January 31, 2008, net cash of $1,825,000 was used in investing activities, primarily for capital expenditures. This compares to the net cash of $1,429,000 used in investing activities in the same period of the prior year, primarily for capital expenditures.

The Company’s financing activities used cash of $64,000 during the nine months ended January 31, 2008. Cash used included $530,000 for cash dividends paid and $266,000 for payments on obligations under capital leases. Cash uses were partially offset by $548,000 received from the exercise of stock options and an increase in short-term borrowings of $184,000. Financing activities used cash of $2,915,000 in the same period of the prior year, which included $524,000 for cash dividends paid, $222,000 for obligations under capital leases, and $2,169,000 for reductions in short-term borrowings.

 

11


Table of Contents

Outlook for Remainder of Fiscal Year 2008

While the Company’s ability to predict future demand for its products continues to be limited given, among other general economic factors affecting the Company and its markets, the Company’s role as subcontractor or supplier to dealers of subcontractors, the Company expects the last quarter of fiscal year 2008 to be profitable and improved over the same period last year. In addition to general economic factors affecting the Company and its markets, demand for the Company’s products is also dependent upon the number of laboratory construction projects planned and/or current progress in projects already under construction. The Company’s earnings may be impacted by increased costs of raw materials, including stainless steel, wood, and epoxy resin, and whether the Company is able to increase product prices to customers in amounts that correspond to such increases without materially and adversely affecting sales.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995

Certain statements in this report constitute “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the “Reform Act”). Such forward-looking statements involve known and unknown risks, uncertainties and other factors that could significantly impact results or achievements expressed or implied by such forward-looking statements. These factors include, but are not limited to, economic, competitive, governmental, and technological factors affecting the Company’s operations, markets, products, services, and prices, as well as prices for certain raw materials and energy. The cautionary statements made pursuant to the Reform Act herein and elsewhere by the Company should not be construed as exhaustive. The Company cannot always predict what factors would cause actual results to differ materially from those indicated by the forward-looking statements. In addition, readers are urged to consider statements that include the terms “believes”, “belief”, “expects”, “plans”, “objectives”, “anticipates”, “intends” or the like to be uncertain and forward-looking. Over time, the Company’s actual results, performance or achievements will likely differ from the anticipated results, performance or achievements that are expressed or implied by the Company’s forward-looking statements, and such differences might be significant and adverse. Factors that could cause such differences are described under the caption “Risk Factors,” in Item 1A of the Company’s 2007 Annual Report on Form 10-K.

 

12


Table of Contents

REVIEW BY INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

A review of the consolidated interim financial information included in this Quarterly Report on Form 10-Q for the three months and nine months ended January 31, 2008 and January 31, 2007 has been performed by Cherry, Bekaert & Holland, L.L.P., the Company's independent auditors. Their report on the consolidated interim financial information follows.

 

13


Table of Contents

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

The Board of Directors and Shareholders

Kewaunee Scientific Corporation

We have reviewed the accompanying consolidated balance sheets of Kewaunee Scientific Corporation and its subsidiaries (the “Company”) as of January 31, 2008, and the related consolidated statements of operations for the three-month and nine-month periods ended January 31, 2008 and 2007 and the related consolidated statements of cash flows for the nine-month periods ended January 31, 2008 and 2007. These interim financial statements are the responsibility of the Company’s management.

We conducted our review in accordance with the standards of the Public Company Accounting Oversight Board (United States). A review of interim financial information consists principally of applying analytical procedures and making inquiries of persons responsible for financial and accounting matters. It is substantially less in scope than an audit conducted in accordance with the standards of the Public Company Accounting Oversight Board (United States), the objective of which is the expression of an opinion regarding the financial statements taken as a whole. Accordingly, we do not express such an opinion.

Based on our review, we are not aware of any material modifications that should be made to the consolidated interim financial statements referred to above for them to be in conformity with accounting principles generally accepted in the United States of America.

We previously audited, in accordance with the Standards of the Public Accounting Oversight Board (United States), the consolidated balance sheet as of April 30, 2007, and the related statements of operations, of stockholder’s equity and of cash flows for the year then ended (not presented herein) and in our report dated July 12, 2007, we expressed an unqualified opinion on those consolidated financial statements. In our opinion, the information set forth in the accompanying consolidated balance sheet as of April 30, 2007 is fairly stated in all material respects in relation to the consolidated financial statement from which it has been derived.

/s/ Cherry, Bekaert & Holland, L.L.P.

Charlotte, North Carolina

March 12, 2008

 

14


Table of Contents
Item 3. Quantitative and Qualitative Disclosures About Market Risk

There are no material changes to the disclosures made on this matter in the Company’s Annual Report on Form 10-K for the fiscal year ended April 30, 2007.

 

Item 4. Controls and Procedures

(a) Evaluation of disclosure controls and procedures

An evaluation was performed under the supervision and the participation of the company’s management, including the Chief Executive Officer (“CEO”) and Chief Financial Officer (“CFO”), of the effectiveness of the design and operation of the Company’s disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended) as of January 31, 2008. Based on that evaluation, the Company’s management, including the CEO and CFO, concluded that, as of January 31, 2008, the Company’s disclosure controls and procedures were adequate and effective and designed to ensure that all material information required to be filed in this quarterly report is made known to them by others within the Company and its subsidiaries.

(b) Changes in internal controls

There was no significant change in the Company’s internal control over financial reporting that occurred during the most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting.

 

15


Table of Contents

PART II. OTHER INFORMATION

 

Item 6. Exhibits and Reports on Form 8-K

 

31.1    Certification of Chief Executive Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2    Certification of Chief Financial Officer pursuant to, Rule 13a-14(a) or Rule 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1    Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
32.2    Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

 

16


Table of Contents

SIGNATURE

Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

    KEWAUNEE SCIENTIFIC CORPORATION
    (Registrant)                    
Date: March 13, 2008     By   /s/ D. Michael Parker
        D. Michael Parker
        (As duly authorized officer and
        Senior Vice President, Finance and
        Chief Financial Officer)

 

17